Literature DB >> 27956696

Targeting the Nuclear Cathepsin L CCAAT Displacement Protein/Cut Homeobox Transcription Factor-Epithelial Mesenchymal Transition Pathway in Prostate and Breast Cancer Cells with the Z-FY-CHO Inhibitor.

Liza J Burton1, Jodi Dougan1, Jasmine Jones1, Bethany N Smith1, Diandra Randle1, Veronica Henderson1, Valerie A Odero-Marah2.   

Abstract

The epithelial mesenchymal transition (EMT) promotes tumor migration and invasion by downregulating epithelial markers such as E-cadherin and upregulating mesenchymal markers such as vimentin. Cathepsin L (Cat L) is a cysteine protease that can proteolytically activate CCAAT displacement protein/cut homeobox transcription factor (CUX1). We hypothesized that nuclear Cat L may promote EMT via CUX1 and that this could be antagonized with the Cat L-specific inhibitor Z-FY-CHO. Mesenchymal prostate (ARCaP-M and ARCaP-E overexpressing Snail) and breast (MDA-MB-468, MDA-MB-231, and MCF-7 overexpressing Snail) cancer cells expressed lower E-cadherin activity, higher Snail, vimentin, and Cat L activity, and a p110/p90 active CUX1 form, compared to epithelial prostate (ARCaP-E and ARCaP-Neo) and breast (MCF-7 and MCF-7 Neo) cancer cells. There was increased binding of CUX1 to Snail and the E-cadherin promoter in mesenchymal cells compared to epithelial prostate and breast cells. Treatment of mesenchymal cells with the Cat L inhibitor Z-FY-CHO led to nuclear-to-cytoplasmic relocalization of Cat L, decreased binding of CUX1 to Snail and the E-cadherin promoter, reversed EMT, and decreased cell migration/invasion. Overall, our novel data suggest that a positive feedback loop between Snail-nuclear Cat L-CUX1 drives EMT, which can be antagonized by Z-FY-CHO. Therefore, Z-FY-CHO may be an important therapeutic tool to antagonize EMT and cancer progression.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CDP/Cux; EMT; Snail; Z-FY-CHO; cathepsin L

Mesh:

Substances:

Year:  2017        PMID: 27956696      PMCID: PMC5311241          DOI: 10.1128/MCB.00297-16

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  21 in total

1.  A novel proteolytically processed CDP/Cux isoform of 90 kDa is generated by cathepsin L.

Authors:  Brigitte Goulet; Mary Truscott; Alain Nepveu
Journal:  Biol Chem       Date:  2006-09       Impact factor: 3.915

2.  CDP/Cux stimulates transcription from the DNA polymerase alpha gene promoter.

Authors:  Mary Truscott; Lélia Raynal; Peter Premdas; Brigitte Goulet; Lam Leduy; Ginette Bérubé; Alain Nepveu
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

3.  Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer.

Authors:  Shane Sullivan; Miriam Tosetto; David Kevans; Alan Coss; Laimun Wang; Diarmuid O'Donoghue; John Hyland; Kieran Sheahan; Hugh Mulcahy; Jacintha O'Sullivan
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

4.  Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition.

Authors:  Binhua P Zhou; Jiong Deng; Weiya Xia; Jihong Xu; Yan M Li; Mehmet Gunduz; Mien-Chie Hung
Journal:  Nat Cell Biol       Date:  2004-09-26       Impact factor: 28.824

5.  Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation.

Authors:  Brigitte Goulet; Laurent Sansregret; Lam Leduy; Matthew Bogyo; Ekkehard Weber; Shyam S Chauhan; Alain Nepveu
Journal:  Mol Cancer Res       Date:  2007-09       Impact factor: 5.852

Review 6.  Cysteine cathepsin proteases as pharmacological targets in cancer.

Authors:  Carmela Palermo; Johanna A Joyce
Journal:  Trends Pharmacol Sci       Date:  2007-11-26       Impact factor: 14.819

Review 7.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

8.  Nuclear cathepsin L activity is required for cell cycle progression of colorectal carcinoma cells.

Authors:  Tripti Tamhane; Rukshala Lllukkumbura; Shiying Lu; Gunhild M Maelandsmo; Mads H Haugen; Klaudia Brix
Journal:  Biochimie       Date:  2015-09-03       Impact factor: 4.079

9.  Snail promotes epithelial mesenchymal transition in breast cancer cells in part via activation of nuclear ERK2.

Authors:  Bethany N Smith; Liza J Burton; Veronica Henderson; Diandra D Randle; Derrick J Morton; Basil A Smith; Latonia Taliaferro-Smith; Peri Nagappan; Clayton Yates; Majd Zayzafoon; Leland W K Chung; Valerie A Odero-Marah
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

Review 10.  Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors.

Authors:  Marton Siklos; Manel BenAissa; Gregory R J Thatcher
Journal:  Acta Pharm Sin B       Date:  2015-09-26       Impact factor: 11.413

View more
  11 in total

1.  Differential impact of RB status on E2F1 reprogramming in human cancer.

Authors:  Christopher McNair; Kexin Xu; Amy C Mandigo; Matteo Benelli; Benjamin Leiby; Daniel Rodrigues; Johan Lindberg; Henrik Gronberg; Mateus Crespo; Bram De Laere; Luc Dirix; Tapio Visakorpi; Fugen Li; Felix Y Feng; Johann de Bono; Francesca Demichelis; Mark A Rubin; Myles Brown; Karen E Knudsen
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

2.  Snail transcription factor NLS and importin β1 regulate the subcellular localization of Cathepsin L and Cux1.

Authors:  Liza J Burton; Veronica Henderson; Latiffa Liburd; Valerie A Odero-Marah
Journal:  Biochem Biophys Res Commun       Date:  2017-07-08       Impact factor: 3.575

3.  Upregulation of homeobox gene is correlated with poor survival outcomes in cervical cancer.

Authors:  Kyung Jin Eoh; Hee Jung Kim; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  Oncotarget       Date:  2017-09-16

4.  Association of Epithelial Mesenchymal Transition with prostate and breast health disparities.

Authors:  Liza J Burton; Ohuod Hawsawi; Quentin Loyd; Veronica Henderson; Simone Howard; Maxine Harlemon; Camille Ragin; Robin Roberts; Nathan Bowen; Andrew Gacii; Valerie Odero-Marah
Journal:  PLoS One       Date:  2018-09-10       Impact factor: 3.240

5.  CCAAT-displacement protein/cut homeobox transcription factor (CUX1) represses estrogen receptor-alpha (ER-α) in triple-negative breast cancer cells and can be antagonized by muscadine grape skin extract (MSKE).

Authors:  Liza J Burton; Ohuod Hawsawi; Janae Sweeney; Nathan Bowen; Tamaro Hudson; Valerie Odero-Marah
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

6.  CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation.

Authors:  Heidi Griesmann; Sebastian Mühl; Jan Riedel; Katharina Theuerkorn; Bence Sipos; Irene Esposito; Gregory B Vanden Heuvel; Patrick Michl
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

7.  Dysregulated expression of homeobox family genes may influence survival outcomes of patients with epithelial ovarian cancer: analysis of data from The Cancer Genome Atlas.

Authors:  Kyung Jin Eoh; Hee Jung Kim; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  Oncotarget       Date:  2017-08-01

8.  Dipalmitoylphosphatidic acid inhibits breast cancer growth by suppressing angiogenesis via inhibition of the CUX1/FGF1/HGF signalling pathway.

Authors:  Jian Chen; Zijun Zhou; Yuying Yao; Jianwei Dai; Dalei Zhou; Lijing Wang; Qian-Qian Zhang
Journal:  J Cell Mol Med       Date:  2018-07-16       Impact factor: 5.310

9.  Cathepsin L secretion by host and neoplastic cells potentiates invasion.

Authors:  Samantha S Dykes; Henrietta O Fasanya; Dietmar W Siemann
Journal:  Oncotarget       Date:  2019-09-17

10.  Cysteine cathepsins are altered by flow within an engineered in vitro microvascular niche.

Authors:  Simone A Douglas; Kristina Haase; Roger D Kamm; Manu O Platt
Journal:  APL Bioeng       Date:  2020-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.